Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|New England Journal of Medicine|2016Cited by 5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerMarshall R. Posner, Robert I. Haddad, Diáne Hershock et al.|New England Journal of Medicine|2007Cited by 1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyDavid G. Pfister, Susan Darlow, Sharon Spencer et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Oral Oncology|2018Cited by 802
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018A. Dimitrios Colevas, Susan Darlow, Robert I. Haddad et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 632